Loss narrows sharply. Dogwood Therapeutics, Inc. (NASDAQ: DWTX) reported a loss of $0.26 per share for Q4 2025, narrower than the estimated loss. The company, which remains pre-revenue as it advances its clinical pipeline, reported a loss of $6.29 per share in the year-ago quarter.
No revenue yet. The company did not generate revenue in Q4 2025, consistent with its status as a clinical-stage biotechnology firm. Trading volume reached 67,899 shares on the report, with the stock closing at $3.22 and a market capitalization of $98.8 million.
Analyst sentiment holds firm. The consensus rating distribution shows 1 Strong Buy and 1 Buy recommendation with no Hold or Sell ratings, unchanged over the past three months.
What to Watch: Monitor the company’s next clinical trial readout and cash runway guidance on the upcoming earnings call.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
Source link
#Dogwood #Therapeutics #DWTX #Earnings #Results
